All Oncology News

Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC

February 16th 2023

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Brexu-cel Shows Survival Benefit in Relapsed/Refractory B-cell ALL, Regardless of Prior Treatment

February 16th 2023

Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.

MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCT

February 16th 2023

The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.

JCAR021 Showcases High Response Rates, but Mixed Safety Data in Relapsed/Refractory Large B-cell Lymphoma

February 16th 2023

The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.

Freshly Infused Zamtocabtagene Autoleucel Shows Encouraging Activity in Relapsed/Refractory DLBCL

February 16th 2023

The dual CD19- and CD20-directed, freshly administered CAR T-cell therapy zamtocabtagene autoleucel elicited a high response rate with deepening responses over time in patients with relapsed/refractory diffuse large B-cell lymphoma.

Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger

February 16th 2023

An independent data monitoring committee has recommended that a phase 3 trial evaluating uproleselan plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia should continue to the planned overall survival event trigger.

Tumor Microbiome Linked to Immunotherapy Success in Sarcoma Patients

February 16th 2023

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer

February 16th 2023

Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.

Ponatinib Plus Reduced-Intensity Chemotherapy Steps Up as Potential New SOC in Newly Diagnosed Ph+ ALL

February 15th 2023

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Toripalimab/Chemo Improves OS in Recurrent/Metastatic Nasopharyngeal Carcinoma in Final JUPITER-02 Trial Analysis

February 15th 2023

Toripalimab plus gemcitabine and cisplatin demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone as frontline therapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Priority Review to Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

February 15th 2023

The FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment.

RxPONDER Analysis Reveals Racial Disparities in HR+/HER2– Breast Cancer

February 15th 2023

Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.

Neoadjuvant Nivolumab Provides Sustained Efficacy in Resected NSCLC

February 15th 2023

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.

Study Confirms Pancreatic Cancer Rates Rising Faster in Women Than Men

February 15th 2023

Cedars-Sinai investigators verify that rates are trending up for both sexes; younger women and Black women see steepest increase.

EPCORE Pushes CD3 × CD20 Bispecific Antibody Into Next Phase of Exploration in DLBCL

February 15th 2023

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

Elacestrant Secures a Place for ER+, HER2–, ESR1-Mutated Advanced/Metastatic Breast Cancer

February 15th 2023

François-Clément Bidard, MD, PhD, discusses how elacestrant fits into the treatment paradigm for postmenopausal patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

FDA Rejects NDA for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma

February 14th 2023

The FDA has issued a refusal to file letter for a new drug application seeking the approval of HyBryte, Soligenix’s synthetic hypericin, for use in patients with early-stage cutaneous T-cell lymphoma.

Brexu-cel Is Effective and Tolerable in Relapsed/Refractory Mantle Cell Lymphoma Beyond ZUMA-2 Population

February 14th 2023

Treatment with brexucabtagene autoleucel in the standard-of-care relapsed/refractory mantle cell lymphoma setting provided an efficacy and safety profile consistent with data reported in the phase 2 ZUMA-2 trial.

Test Document

February 14th 2023

Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer

February 14th 2023

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.